2.48 0.00 (0.00%)
After hours: 5:31PM EST
|Bid||2.46 x 4000|
|Ask||2.50 x 1000|
|Day's Range||2.2700 - 2.5200|
|52 Week Range||1.6500 - 5.0500|
|Beta (3Y Monthly)||1.33|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.42|
NEW YORK, Jan. 09, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Over 800 patients from AcelRx studies supporting DSUVIA™ approval were included in the pooled safety analysis - Initial dosing of 30 mcg sufentanil sublingual tablet calculated as dose-equivalent to ...
Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost around 20%. Facebook, which was the second most popular stock, lost 14% amid uncertainty regarding the interest rates and tech valuations. […]
Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.
REDWOOD CITY, Calif. , Dec. 18, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative ...
Update on DSUVIA U.S. commercialization strategy and insights from key healthcare professionals REDWOOD CITY, Calif. , Nov. 29, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), ...
CORAL GABLES, FL / ACCESSWIRE / November 21, 2018 / Healthcare stocks continue to gain traction amid volatile market conditions this week. Investors have been less optimistic on tech stocks and more favorable to the healthcare sector. US midterm elections have also helped to boost a more favorable market for healthcare.
REDWOOD CITY, Calif. , Nov. 14, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
After earning FDA marketing approval for a controversial new drug, the company is raising cash through a share offering.
REDWOOD CITY, Calif., Nov. 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) today announced the pricing of its previously announced underwritten public offering of 12,698,412 shares of its common stock, at a public offering price of $3.15 per share. All of the shares in the offering are to be sold by AcelRx. The offering is expected to close on or about November 14, 2018, subject to the satisfaction of customary closing conditions.
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
REDWOOD CITY, Calif., Nov. 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. AcelRx expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. Credit Suisse Securities (USA) LLC, Jefferies LLC, Cantor Fitzgerald & Co. and RBC Capital Markets, LLC are acting as joint book-running managers for the offering.
REDWOOD CITY, Calif. , Nov. 7, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
Critics worried about putting such a potent and addictive medication on the market in the midst of the U.S.’s opioid crisis.
More health care issues are being decided at the ballot box, and Tuesday's election isn't the end of the trend.
Healthcare has become the latest market to take full advantage of this trend. According to a paper by PwC called The Digital Healthcare Leap, the new trends are ripe for digital healthcare solutions in developed and emerging markets. As a result, the industry has expanded its focus to non-critical health care services to cater to this changing demand of present-day consumers.
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / AcelRx Pharmaceuticals saw big gains this past Friday after announcing third quarter results and an update on DSUVIA receiving FDA approval. Shares of Sage Therapeutics were halted after its treatment Zulresso, was recommended by an FDA approval for postpartum depression. AcelRx Pharmaceuticals, Inc. shares closed up 15.66% on about 20 million shares traded on Friday.
Headed into today’s action following Friday’s mostly uncommitted action, stock charts of Coca-Cola (NYSE:KO), Kinder Morgan (NYSE:KMI) and Adobe (NASDAQ:ADBE) are shaping up as your best trading bets. Coca-Cola shares had been trapped in a trading range as of August, but that range was finally broken this week. • In the weekly timeframe we can see a long-term trading range has also guided Coca-Cola shares upward since 2013.
The Food and Drug Administration on Friday approved a powerful new opioid drug called Dsuvia that has possible uses for treating wounded soldiers on the battlefield. Consumer representatives say the drug is especially potent and particularly susceptible to abuse. Balancing those dangers against needs for powerful painkillers in certain settings has been a dilemma for the FDA amid a national overdose epidemic.
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -5.00% and -65.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Redwood City, California-based company said it had a loss of 21 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...